Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in
combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of
adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become
refractory to asparaginase-based regimens.